Nicolas Barbezier Selected Research

6-aminophenanthridine

1/2011

Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicolas Barbezier Research Topics

Disease

3	Oculopharyngeal Muscular Dystrophy 01/2022 - 01/2011
1	Muscular Atrophy (Muscle Atrophy) 01/2022
1	Colitis 07/2019
1	Inflammation (Inflammations) 07/2019
1	Late Onset Disorders 03/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2015
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2015
1	Renal Insufficiency (Renal Failure) 11/2014

Drug/Important Bio-Agent (IBA)

1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022
1	UbiquitinIBA 01/2022
1	IronIBA 07/2019
1	salicylhydroxamic acid (SHAM)IBA 07/2019
1	Peroxidase (Myeloperoxidase)IBA 07/2019
1	Sulfonic AcidsIBA 07/2019
1	Messenger RNA (mRNA)IBA 03/2015
1	polyalanineIBA 03/2015
1	Poly(A)-Binding Protein IIIBA 03/2015
1	Advanced Glycation End ProductsIBA 11/2014
1	Guanabenz (BR 750)FDA Link 01/2011
1	6-aminophenanthridineIBA 01/2011